Madrigal Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 9 | -$7.88 | -$3.91 | -$6.29 |
| Q2 2024 | 4 | -$9.45 | -$4.68 | -$7.54 |
| Q3 2024 | 4 | -$8.46 | -$4.19 | -$6.75 |
| Q4 2024 | 11 | -$6.03 | -$3.74 | -$4.51 |
| Q1 2025 | 6 | -$4.61 | -$3.08 | -$3.83 |
| Q2 2025 | 5 | -$4.17 | -$2.07 | -$3.32 |
| Q3 2025 | 5 | -$3.60 | -$1.78 | -$2.87 |
| Q4 2025 | 5 | -$2.92 | -$1.45 | -$2.33 |
| Q1 2026 | 2 | -$3.87 | -$1.92 | -$3.09 |
| Q2 2026 | 2 | -$2.64 | -$1.31 | -$2.11 |
| Q3 2026 | 2 | -$0.80 | -$0.40 | -$0.64 |
| Q4 2026 | 2 | $4.69 | $9.45 | $7.54 |
Madrigal Pharmaceuticals, Inc. Earnings Date And Information
Madrigal Pharmaceuticals, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $-4.92 earnings per share for the quarter, topping analysts' consensus estimates of $-6.94 by $2.02. The company had revenue of 62.18 M for the quarter and had revenue of 0 for the year. Madrigal Pharmaceuticals, Inc. has generated $-20 earnings per share over the last year ($-19.99 diluted earnings per share) and currently has a price-to-earnings ratio of -14.57. Madrigal Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Madrigal Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | -$6.94 | -$4.92 | 2.02 | $34.60 M | $62.18 M |
| 08/07/2024 | Q2 2024 | -$7.55 | -$7.10 | 0.45 | $4.25 M | $14.64 M |
| 05/07/2024 | Q1 2024 | -$6.06 | -$7.38 | -1.32 | $0 | |
| 02/28/2024 | Q4 2023 | -$5.32 | -$5.68 | -0.36 | $770,000 | |
| 11/06/2023 | Q3 2023 | -$4.78 | -$5.34 | -0.56 | $0 | |
| 08/08/2023 | Q2 2023 | -$4.47 | -$4.69 | -0.22 | $0 | |
| 05/09/2023 | Q1 2023 | -$4.98 | -$4.28 | 0.7 | $0 | |
| 03/03/2023 | Q4 2022 | -$5.08 | $0 | |||
| 11/03/2022 | Q3 2022 | -$4.05 | -$4.84 | -0.79 | $0 | |
| 08/04/2022 | Q2 2022 | -$3.76 | -$4.18 | -0.42 | $0 | |
| 05/09/2022 | Q1 2022 | -$3.75 | -$3.37 | 0.38 | $0 | |
| 02/24/2022 | Q4 2021 | -$3.92 | -$3.78 | 0.14 | $0 | |
| 11/04/2021 | Q3 2021 | -$3.89 | -$3.79 | 0.1 | $0 | |
| 08/05/2021 | Q2 2021 | -$3.55 | -$3.72 | -0.17 | $0 | |
| 05/06/2021 | Q1 2021 | -$3.78 | -$3.32 | 0.46 | $0 | |
| 02/25/2021 | Q4 2020 | -$3.82 | -$3.82 | 0 | $0 | |
| 11/05/2020 | Q3 2020 | -$3.35 | -$3.75 | -0.4 | $0 | |
| 08/06/2020 | Q2 2020 | -$2.42 | -$3.18 | -0.76 | $0 | |
| 05/07/2020 | Q1 2020 | -$1.94 | -$2.34 | -0.4 | $0 | |
| 02/26/2020 | Q4 2019 | -$1.56 | -$1.80 | -0.24 | $0 |
Madrigal Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Madrigal Pharmaceuticals, Inc.'s earnings date?
Madrigal Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
Did Madrigal Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Madrigal Pharmaceuticals, Inc. (:MDGL) reported $-4.92 earnings per share (EPS) to beat the analysts' consensus estimate of $-6.94 by $2.02.
-
How can I listen to Madrigal Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Madrigal Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Madrigal Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Madrigal Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much profit does Madrigal Pharmaceuticals, Inc. generate each year?
Madrigal Pharmaceuticals, Inc. (:MDGL) has a recorded net income of $0. Madrigal Pharmaceuticals, Inc. has generated $-19.99 earnings per share over the last four quarters.
-
What is Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio?
Madrigal Pharmaceuticals, Inc. (:MDGL) has a price-to-earnings ratio of -14.57 and price/earnings-to-growth ratio is -8.84.
